ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RTW Rtw Biotech Opportunities Ltd

1.30
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Rtw Biotech Opportunities Ltd RTW London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 1.30 01:00:00
Open Price Low Price High Price Close Price Previous Close
1.30
more quote information »

Rtw Biotech Opportunities RTW Dividends History

No dividends issued between 01 May 2014 and 01 May 2024

Top Dividend Posts

Top Posts
Posted at 23/3/2024 20:39 by rambutan2
Apogee (APGE) is another big, up 50%, riser this month on the back of trial news and subsequent raise. RTW was a backer from pre IPO at multiples lower.
Posted at 21/3/2024 22:09 by rambutan2
Yes, very wrongly priced currently. The sector trades on around a 10% discount, so this has got really out of wack. And especially so considering it is a top performer and has a quality manager. It offers a rare opportunity to buy a real no brainer. imho.

Sector stats:


I note that in the last fact sheet, Avidity came from nowhere to be 9% of nav. Since then, it is up approx 40% on good news and a fund raise in which RTW participated. This just illustrates one of the great advantages offered by being part of the RTW platform, one of the elite bio investors in the States.
Posted at 21/2/2024 19:10 by rimau1
Its a good question, not really small single digit accretive was it!! They have set out all the reasons why a downward revision could have occurred since 31 Jan. Most likely is that they have now applied the RTW valuation methodology to the Arix privately held assets. I also think the the Jan 31 NAV of $1.94 was artificially high since it included the 25.5% stake in Axis that they had purchased for £1.37 which was worth £1.44 at 31 Jan. Just a guess.
Posted at 21/2/2024 15:10 by jaf111
Agree that it certainly looks attractive but have to admit being very disappointed with the $1.88 proforma number.
When the “merger” was announced last November RTW stated it was expected to be immediately accretive to RTW NAV per share……
But the end Jan (pre merger) NAV was $1.94 per share……..
Have I missed something??????
Posted at 14/2/2024 08:19 by rimau1
Of course there are Weatherman, its much more complicated than that as you know. Quality of management team, composition of holdings, sector, exit opportunities/realisations/news pipeline/cash available for new investments/accretive buyback appetite/historic performance. I would venture that RTW ticks all the boxes for me personally.
Posted at 09/5/2023 22:48 by rambutan2
RTW Venture Fund Limited (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, is pleased to note the announcement by one of its portfolio companies, Acelyrin, Inc. ("Acelyrin") regarding its pricing of an upsized $540 million initial public offering ("IPO") and admission to trade on Nasdaq Global Market under ticker "SLRN".

Acelyrin is a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology. Its lead product candidate, Izokibep, is a small protein therapeutic designed to inhibit interleukin-17A (IL-17A) with high potency and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. Izokibep is in late-stage clinical development across multiple indications including hidradenitis suppurative, psoriatic arthritis, uveitis and axial spondylarthritis.

Prior to IPO, the Company, together with other funds managed by RTW Investments, LP (the "Investment Manager"), participated in Acelyrin's $250 million Series B financing round in November 2021.

Acelyrin's IPO raised $540 million by offering 30 million shares at $18.00 per share. On the first day of trading, Acelyrin's share price traded up by 30.55% to close at $23.50 per share.

Roderick Wong, MD, Managing Partner and Chief Investment Officer at the Investment Manager, said:
"We are excited about Acelyrin's successful debut on the public markets, the third from our portfolio this year in an otherwise challenging capital market, and we look forward to supporting the company in its efforts to develop new treatments for inflammatory conditions. "
Posted at 06/5/2023 04:08 by rambutan2
Good interview with another top bio crossover investor, Dr. Chen Yu, Founder & Managing Partner at TCGX. Many similarities to RTW. And like them, he's currently pretty bullish.
Posted at 27/4/2023 16:43 by rambutan2
A worthwhile listen:

Rod Wong is the founder and Managing Partner of RTW Investments, a life sciences-focused investment and innovation firm of 80 professionals that manages $6 billion in assets.

I had a chance to drop by Rod’s office in NYC and discuss his background, case for life sciences, investment and business approach, investment process across sourcing ideas, research, probability assessment of binary outcomes, portfolio construction, competition, and outlook.
Posted at 17/4/2023 15:30 by rambutan2
And back up we go, thanks to this timely takeover!

RTW Venture Fund Limited (the "Company" or "RTW Venture Fund"), a London Stock Exchange-listed investment fund focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Prometheus Biosciences, Inc. (NASDAQ: RXDX) ("Prometheus"), that it has entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion, a c. 75% premium to the prior closing price. The acquisition is subject to Prometheus Biosciences shareholder approval and is expected to close in the third quarter of 2023.

Prometheus is the largest holding in RTW Venture Fund's portfolio, representing c. 14.8% of NAV at 31 March 2023. As such, the Company expects that this will translate into a material accretion to the NAV.
Posted at 31/3/2023 22:36 by rambutan2
AR out today. I recently took a small position in what I think is the pick of the Bio trusts:

Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP (the "Investment Manager") commented:
"We are pleased to report another robust set of results for the RTW Venture Fund in 2022. We find ourselves in unprecedented market conditions, having witnessed the second consecutive year of a bear market in the biotech sector.

"Given these challenging times, we are happy to report that the Group has once again significantly outperformed the Russell 200 Biotech Index (the most appropriate performance comparator), with a -10.2% NAV return for the period, against a -31.3% return for the Index.

"The Group's successful strategy of selecting high-quality transformative assets with significant growth potential could be seen in our core portfolio, which held up well, contributing +0.2% to NAV during 2022. Whilst only a modest return, it compares favourably to the weak performance of the Group's sector indices.

"Due to the adverse market conditions, 2022 saw just two of our portfolio companies IPO. RTW added three new companies to the portfolio and disposed of seven. Disposals crystalised a +1.6% contribution to NAV for the year with the proceeds being redeployed into other public opportunities.

"Most importantly, we continue to see public market valuations at significant discounts to historic levels, providing extremely compelling investment opportunities, with many of potential best-in-class therapeutics trading at notable lows compared to their long-term benchmarks. Our resources and expertise place us in an excellent position to capitalise on these trends and achieve significant value for shareholders over the medium- to long-term."



Research:

Reported manager positions:

Index:

Your Recent History

Delayed Upgrade Clock